Karuna Therapeutics Stock: Front-Running KarXT Phase 3 (NASDAQ:KRTX)
janiecbros/E+ via Getty Images With biotech back momentarily in vogue this month, investors might find it worthwhile to re-acquaint themselves with Karuna Therapeutics (NASDAQ:KRTX). This clinical-stage biopharmaceutical company was the best first-year IPO performer of […]
